【百利天恒:宜泽康III期临床试验完成首例受试者入组】百利天恒公告,公司自主研发的全球首创、新概念、全球首个且唯一获批上市的EGFR×HER3双抗ADC宜泽康®用于治疗含铂放化疗后未出现进展的不可切除EGFR突变型III期非小细胞肺癌患者中对比BL-B01D1联合奥希替尼与奥希替尼单药的III期随机对照临床试验已于近日完成首例受试者入组。截至目前,宜泽康®已在中国和美国开展了超45项针对多种肿瘤类型的临床试验,其中,III期临床研究20项。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.